Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK Health Body Approves Novartis's Tasigna For CML

04/24/2012 | 07:16pm US/Eastern

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

React to this article
Latest news on NOVARTIS AG
07/30DJAmgen Raises 2015 Outlook, Results Beat Expectations -- 2nd Update
07/30DJAmgen Raises 2015 Outlook, Results Beat Expectations
07/30 Teva's MS drug Copaxone has strong second-quarter sales
07/30 NOVARTIS : Mereo BioPharma Acquires Clinical Assets from Novartis
07/29 IGNYTA : Boosts Leadership Capacity with Appointment of Bernard Parker as Chief ..
07/29 NOVARTIS : Forma Therapeutics Appoints John Hohneker, M.D., as Executive Vice Pr..
07/29 GLAXOSMITHKLINE : GSK shares rise after earnings beat estimates
07/29 2ND UPDATE : GlaxoSmithKline On Track For 2015 And Confident For 2016
07/29 GSK flags up pipeline as HIV drugs help it beat profit forecasts
07/29 GSK flags up pipeline as HIV drugs help it beat profit forecasts
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
More Financials